|
HBV |Abstract Library |
|
|
The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
Abstract Details |
|
|
|
|
|
|
|
|
The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study |
|
|
|
|
|
HIV Med. 2022 Jul;23(6):585-598. doi: 10.1111/hiv.13210. Epub 2021 Dec 9.
Amanda Mocroft 1 2, Jose M Miro 3, Gilles Wandeler 4, Josep M Llibre 5, Anders Boyd 6 7, Kathrin van Bremen 8, Marek Beniowski 9, Julia Mikhalik 10, Matthias Cavassini 11, Fernando Maltez 12, Claudine Duvivier 13 14 15 16, Caterina Uberti Foppa 17, Brygida Knysz 18, Elzbieta Bakowska 19, Elena Kuzovatova 20, Pere Domingo 21, Alexandra Zagalo 22, Jean-Paul Viard 23, Olaf Degen 24, Ana Milinkovic 25, Thomas Benfield 26, Lars Peters 1, EuroSIDA study group
|
|
|
|
|
Author information
Collaborators
A Harxhi, M Losso, M Kundro, B Schmied, R Zangerle, I Karpov, A Vassilenko, V M Mitsura, D Paduto, N Clumeck, S De Wit, M Delforge, E Florence, L Vandekerckhove, V Hadziosmanovic, J Begovac, L Machala, D Sedlacek, G Kronborg, J Gerstoft, T Katzenstein, C Pedersen, I S Johansen, L Ostergaard, L Wiese, N F Moller, L N Nielsen, K Zilmer, J Smidt, I Aho, K Lacombe, C Pradier, E Fontas, J Rockstroh, G Behrens, C Hoffmann, H J Stellbrink, C Stefan, J Bogner, G Fätkenheuer, N Chkhartishvili, H Sambatakou, G Adamis, N Paissios, J Szlávik, M Gottfredsson, E Devitt, L Tau, D Turner, M Burke, E Shahar, L M Wattad, H Elinav, M Haouzi, D Elbirt, A D'Arminio Monforte, R Esposito, I Mazeu, C Mussini, F Mazzotta, A Gabbuti, A Lazzarin, A Castagna, N Gianotti, M Galli, A Ridolfo, V Uzdaviniene, R Matulionyte, T Staub, R Hemmer, S Dragas, M Stevanovic, M Vd Valk, J Trajanovska, D H Reikvam, A Maeland, J Bruun, B Szetela, M Inglot, R Flisiak, A Grzeszczuk, M Parczewski, K Maciejewska, B Aksak-Was, E Mularska, E Jablonowska, J Kamerys, K Wojcik, I Mozer-Lisewska, B Rozplochowski, K Mansinho, R Radoi, C Oprea, D Gusev, T Trofimova, I Khromova, E Borodulina, J Ranin, J Tomazic, J M Miró, M Laguno, E Martinez, F Garcia, J L Blanco, M Martinez-Rebollar, J Mallolas, P Callau, J Rojas, A Inciarta, S Moreno, S Del Campo, B Clotet, A Jou, R Paredes, J Puig, J R Santos, M Gutierrez, G Mateo, M A Sambeat, J M Laporte, V Svedhem, A Thalme, A Sönnerborg, J Brännström, L Flamholc, K Kusejko, D Braun, A Calmy, H Furrer, M Battegay, P Schmid, A Kuznetsova, M Sluzhynska, A M Johnson, E Simons, S Edwards, A Phillips, M A Johnson, C Orkin, A Winston, A Clarke, C Leen, I Karpov, M Losso, J Lundgren, J Rockstroh, I Aho, L D Rasmussen, V Svedhem, C Pradier, N Chkhartishvili, R Matulionyte, C Oprea, J D Kowalska, J Begovac, J M Miró, G Guaraldi, R Paredes, R Paredes, J F Larsen, A Bojesen, B Neesgaard, N Jaschinski, O Fursa, M Sather, D Raben, E V Hansen, D Kristensen, A H Fischer, S K Jensen, T W Elsing, A Phillips, J Reekie, A Cozzi-Lepri, S Amele, A Pelchen-Matthews, A Roen, E S Tusch, W Bannister
Affiliations
- 1CHIP, Rigshospitalet, Copenhagen, Denmark.
- 2Centre for Clinical Research Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, University College London, London, UK.
- 3Hospital Clinic-IDIBAPS University of Barcelona, Barcelona, Spain.
- 4Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
- 5Infectious Diseases Unit & Fight AIDS Foundation, Hospital Germans Trias i Pujol, Badalona, Spain.
- 6Stichting HIV Monitoring (SHM), Amsterdam, the Netherlands.
- 7Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands.
- 8Department of Medicine, University Hospital Bonn, Bonn, Germany.
- 9Diagnostics and Therapy for AIDS, Specialistic Hospital, Chorzów, Poland.
- 10Crimean Republican AIDS Centre, Simferopol, Ukraine.
- 11Service of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- 12Curry Cabral Hospital, Lisbon, Portugal.
- 13AP-HP-Necker Hospital, Infectious Diseases Department, Necker-Pasteur Infectiology Center, Paris, France.
- 14University of Paris, INSERM U1016, Paris, France.
- 15HU Imagine, Paris, France.
- 16Institut Pasteur, Institut Pasteur Medical Center, Paris, France.
- 17Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy.
- 18Wroclaw Medical University, Wroclaw, Poland.
- 19Hospital for Infectious Diseases in Warsaw, Warsaw, Poland.
- 20Academician I.N. Blokhina Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology, Nizhny Novgorod, Russia.
- 21Department of Infectious Diseases, Hospital of the Holy Cross and Saint Paul, Barcelona, Spain.
- 22Department of Infectious Diseases, Santa Maria University Hospital, Lisbon, Portugal.
- 23Diagnostic and Therapeutic Center, Hôtel-Dieu, AP-HP, Paris, France.
- 24University Clinic Hamburg Eppendorf, Hamburg, Germany.
- 25Chelsea and Westminster Hospital, London, UK.
- 26Department of Infectious Diseases, Copenhagen University Hospital-Amager and Hvidovre, Hvidovre, Denmark.
Abstract
Objectives: The aim of this study was to assess the impact of hepatitis B virus (HBV) infection on non-liver malignancies in people living with HIV (PLWH).
Methods: All persons aged ≥ 18 years with known hepatitis B virus (HBV) surface antigen (HBsAg) status after the latest of 1 January 2001 and enrolment in the EuroSIDA cohort (baseline) were included in the study; persons were categorized as HBV positive or negative using the latest HBsAg test and followed to their first diagnosis of nonliver malignancy or their last visit.
Results: Of 17 485 PLWH included in the study, 1269 (7.2%) were HBV positive at baseline. During 151 766 person-years of follow-up (PYFU), there were 1298 nonliver malignancies, 1199 in those currently HBV negative [incidence rate (IR) 8.42/1000 PYFU; 95% confidence interval (CI) 7.94-8.90/1000 PYFU] and 99 in those HBV positive (IR 10.54/1000 PYFU; 95% CI 8.47-12.62/1000 PYFU). After adjustment for baseline confounders, there was a significantly increased incidence of nonliver malignancies in HBV-positive versus HBV-negative individuals [adjusted incidence rate ratio (aIRR) 1.23; 95% CI 1.00-1.51]. Compared to HBV-negative individuals, HBsAg-positive/HBV-DNA-positive individuals had significantly increased incidences of nonliver malignancies (aIRR 1.37; 95% CI 1.00-1.89) and NHL (aIRR 2.57; 95% CI 1.16-5.68). There was no significant association between HBV and lung or anal cancer.
Conclusions: We found increased rates of nonliver malignancies in HBsAg-positive participants, the increases being most pronounced in those who were HBV DNA positive and for NHL. If confirmed, these results may have implications for increased cancer screening in HIV-positive subjects with chronic HBV infection.
|
|
|
|
|
|
|
|
|
|
|
|
|